Inhaled antimicrobial therapy - Barriers to effective treatment

Advanced Drug Delivery Reviews

Volumn 85, Issue , 2015, Pages 24-43

  Weers, Jeffry ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Biofilm; Dry powder inhaler; Endpoint; Fixed dose combination; Nebulizer; Partial liquid ventilation; Tolerability

Indexed keywords

ANTIBIOTICS; BIOFILMS;

DRY POWDER INHALER; ENDPOINT; FIXED-DOSE COMBINATION; NEBULIZER; PARTIAL LIQUID VENTILATION; TOLERABILITY;

DRUG DELIVERY;

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIBIOTIC AGENT; AZTREONAM; CIPROFLOXACIN; COLISTIMETHATE; FOSFOMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ATYPICAL MYCOBACTERIOSIS; BACTERIAL COLONIZATION; BIOFILM; BREATHING MECHANICS; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; COMPUTATIONAL FLUID DYNAMICS; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYSTIC FIBROSIS; DEVICE SAFETY; DISEASE EXACERBATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDICATION; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRY POWDER INHALER; DYSGEUSIA; DYSPHONIA; DYSPNEA; EQUIPMENT DESIGN; FEVER; HUMAN; JET NEBULIZER; LIQUID VENTILATION; LUNG ASPERGILLOSIS; LUNG DISEASE; LUNG GAS EXCHANGE; MAXIMUM PLASMA CONCENTRATION; MICROBIOME; MUCOCILIARY CLEARANCE; MULTIDRUG RESISTANCE; NEBULIZER; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; RISK BENEFIT ANALYSIS; TUBERCULOSIS; VENTILATOR ASSOCIATED PNEUMONIA; VIBRATING MESH NEBULIZER; DEVICES; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ECONOMICS; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; PNEUMONIA, VENTILATOR-ASSOCIATED; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; NEBULIZERS AND VAPORIZERS; PNEUMONIA, VENTILATOR-ASSOCIATED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS;

EID: 84930088821     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.08.013     Document Type: Review

References (210)

1. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., Scheld M., Spellberg B., Bartlett J. Bad bugs, no drugs: no ESKAPE!: an update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 48:1-12.
2. Boucher H.W., Talbot G.H., Benjamin D.K., Bradley J., Guidos R.J., Jones R.N., Murray B.E., Bonomo R.A., Gilbert D. 10 x '20 progress - development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2013, 56:1685-1694.
3. Geller D.E. Aerosol antibiotics in cystic fibrosis. Respir. Care 2009, 54:658-670.
4. Hofmann T. New developments in inhaled antibiotics for the treatment of Pseudomonas aeruginosa. Curr. Pharm. Des. 2012, 18:683-695.
5. Cipolla D., Chan H.K. Inhaled antibiotics to treat lung infection. Pharm. Pat. Analyst 2013, 2:647-663.
6. Luyt C.E., Brechot N., Trouillet J.L., Chastre J. Delivering antibiotics to the lungs of patients with ventilator-associated pneumonia: an update. Expert Rev. Anti-Infect. Ther. 2013, 11:511-521.
7. Wilson R., Sethi S., Anzueto A., Mravitlles M. Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. J. Infect. 2013, 67:497-515.
8. Quon B.S., Goss C.H., Ramsey B.W. Inhaled antibiotics for lower airway infections. Ann. Am. Thorac. Soc. 2014, 11:425-434.
9. Henry R.L., Mellis C.M., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr. Pulmonol. 1992, 12:158-161.
10. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr. Pulmonol. 2002, 34:91-100.
11. Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., Vasiljev M., Borowitz D., Bowman C.M., Marshall B.C., Marshall S., Smith A.J. Intermittant administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1999, 340:23-30.
12. Sawicki G.S., Sinorovitch J.E., Zhang J., Latremouille D., von Wartburg M., Wu E.Q., Shi L. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr. Pulmonol. 2012, 47:44-52.
13. D'ring G., Flume P., Heijerman H., Elborn J.S. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 2012, 11:461-479.
14. Costerton J.W., Lewanddowski Z., DeBeer D., Caldwell D., Korber D., James G. Biofilms, the customized microniche. J. Bacteriol. 1994, 176:2137-2142.
15. del Pozo J.L., Patel R. The challenge of treating biofilm-associated bacterial infections. Clin. Pharmacol. Ther. 2007, 82:204-209.
16. Høiby N., Ciofu O., Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 2010, 5:1663-1674.
17. Ratjen F., Munck A., Kho P., Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010, 65:286-291.
18. Høiby N., Frederiksen B., Pressler T. Eradication of early Pseudomonas aeruginosa infection. J. Cyst. Fibros. 2004, 4(Suppl. 2):49-54.
19. Labiris R., Dolovich M. Pulmonary drug delivery. Part 1: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 2003, 56:588-599.
20. Weycker D., Edelsberg J., Oster G., Tino G. Prevalence and economic burden of bronchiectasis. Clin. Pulm. Med. 2005, 12:205-209.
21. Justo J., Danziger L.H., Gottfried M.H. Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis. Ther. Adv. Respir. Dis. 2013, 7:272-287.
22. Rubin B.K. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J. Aerosol Med. Pulm. Drug Deliv. 2008, 21:71-76.
23. Pasteur M.C., Bilton D., Hill A.T. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010, 65(Suppl. 1):i1-i58.
24. Barker A.F., Couch L., Fiel S.B., Gottfried M.H., Ilowite J., Meyer K.C., O'Donnell A., Sahn S.A., Smith L.J., Stewart J.O., Abuan T., Tally H., Van Dalfsen J., Wells C.D., Quan J. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. 2000, 162:481-485.
25. Couch L.A. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001, 120:114S-117S.
26. Drobnic M.E., Suňé P., Montero J.B., Ferrer A., Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann. Pharmacother. 2005, 39:39-44.
27. Bilton D., Henig N., Morrissey B., Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006, 130:1503-1510.
28. Murray M.P., Govan J.R., Doherty C.J., Simpson A.J., Wilkinson T.S., Chalmers J.D., Greening A.P., Haslett C., Hill A.T. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2011, 183:491-499.
29. Serisier D.J., Bilton D., DeSoyza A., Thompson P.J., Kolbe J., Greville H.W., Cipolla D., Bruinenberg P., Gonda I. Inhaled dual release liposomal ciprofloxacin in non-cystic fibrosis (ORBIT-2): a randomized, double-blind, placebo-controlled trial. Thorax 2013, 68:812-817.
30. Wilson R., Welte T., Polverino E., DeSoyza A., Greville H., O'Donnell A., Alder J., Reimnitz P., Hampel B. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur. Respir. J. 2013, 41:1107-1115.
31. A study to determine the safety and tolerability of Arikace versus placebo in patients who have bronchiectasis (accessed 4/15/2014). http://www.clinicaltrials.gov/ct2/show/NCT00775138?term=Arikace&rank=1.
32. A study to see if AZLI (an inhaled antibiotic) is effective in treating adults with non-CF bronchiectasis - AIR-BX2 (accessed 4/15/2014). http://www.clinicaltrials.gov/ct2/show/NCT01314716?term=AZLI&rank=8.
33. Mannino D.M., Buist A.S. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007, 370:765-773.
34. Wilkinson T.M.A., Patel I.S., Wilks M., Donaldson G.C., Wedzicha J.C. Airway bacterial load and FEV decline in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003, 167:1090-1095.
35. White A.J., Gompertz S., Bayley D.L., Hill S.L., O'Brien C., Unsal I., Stockley R.A. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003, 58:680-685.
36. Anzueto A., Sethi S., Martinez F.J. Exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2007, 4:554-564.
37. Suissa S., Dell'Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012, 67:957-963.
38. Rosell A., Monso E., Soler N., Torres F., Angrill J., Riise G., Zalacain R., Morera J., Torres A. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch. Intern. Med. 2005, 165:891-897.
39. Stockley R.A., O'Brien C., Pye A., Hill S.L. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000, 117:1638-1645.
40. Sethi S., Evans N., Grant B.J.B., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J. Med. 2002, 347:465-471.
41. Murphy T.F., Brauer A.L., Eschberger K., Lobbins P., Grove L., Cai X., Sethi S. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008, 1-46.
42. Adams S.G., Melo J., Luther M., Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000, 117:1345-1352.
43. Wilson R., Anzueto A., Miravitlles M., Arvis P., Alder J., Haverstock D., Trajanovic M., Sethi S. Moxifloxacin vs. amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur. Respir. J. 2012, 40:17-27.
44. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations in chronic bronchitis. Chest 2005, 127:2231-2236.
45. Sethi S., Rennard S.I., Miravitlles M., Martinez F.J., Donohue J.F., Anzueto A., Grossman R., Loutit J., Dudley M.N. A phase 2 study to evaluate the safety, tolerability, and efficacy of levofloxacin inhalation solution (MP-376) administered for 5days every 28days to prevent acute exacerbations in high risk COPD patients. Am. J. Respir. Crit. Care Med. 2012, 185:A3037.
46. Muscedere J.G., Day A., Heyland D.K. Mortality, attributable mortality, and clinical events and endpoints for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia. Clin. Infect. Dis. 2010, 51(Suppl. 1):S120-S125.
47. MacIntyre N.R., Rubin B.K. Should aerosolized antibiotics be administered to prevent or treat ventilator-associated pneumonia in patients who do not have cystic fibrosis?. Respir. Care 2007, 52:416-421.
48. Gaynes R.T., Edwards J.R. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 2005, 41:848-854.
49. Rello J., Ollendorf D.A., Oster G., Vera-Llonch M., Bellm L., Redman R., Kollef M.H. Epidemiology and outcomes of ventilator-associated pneumonia in a large U.S. database. Chest 2002, 122:2115-2121.
50. Luyt C.E., Clavel M., Guntapalli K., Johannigman J., Kennedy J.I., Wood C., Corkery K., Gribben D., Chastre J. Pharmacokinetics and lung delivery of PDDS-aeroslized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit. Care 2009, 13:R200.
51. Niederman M.S., Chastre J., Corkery K., Fink J.B., Luyt C.E., Garcia M.S. BAY41-6551 achieves bactericidal tracheal aspirate concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med. 2012, 38:263-271.
52. Montgomery A.B., Vallance S., Abuan T., Tservistas M., Davies A. A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered with the PARI Investigational eFlow Inline Nebulizer System in mechanically ventilated patients. J. Aerosol Med. Pulm. Drug Deliv. 2014, (in press). 10.1089/jamp.2013.1100.
53. Czosnowski Q.A., Wood G.C., Magnotti L.J., Croce M.A., Swanson J.M., Boucher B.A., Fabian T.C. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy 2009, 29:1054-1060.
54. Palmer L.B., Smalldone G.C., Chen J.J., Baram D., Duan T., Monteforte M., Varela M., Tempone A.K., O'Riordan T., Daroowalla F., Richman P. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit. Care Med. 2008, 36:2008-2013.
55. Lu Q., Luo R., Bodin L., Yang J., Zahr N., Aubry A., Golmard J.-L., Rouby J.-J. Efficacy of high-dose nebulized colisitin in ventilator-associated pneumonia caused by multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 2012, 117:1335-1347.
56. Arnold H.M., Sawyer A.M., Kollef M.H. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir. Care 2012, 57:1226-1233.
57. Craven D.E., Hjalmarson K.I. Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box. Clin. Infect. Dis. 2010, 51(S1):S59-S66.
58. Abu-Salah T., Dhand R. Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update. Adv. Ther. 2011, 28:728-747.
59. Nseir S., Ader F., Marquette C.H. Nosocomial tracheobronchitis. Curr. Opin. Infect. Dis. 2009, 22:148-153.
60. Misra A., Hickey A.J., Rossi C., Borchard G., Terada H., Makino K., Fourie P.B., Colombo P. Inhaled drug therapy for treatment of tuberculosis 2011, 91:71-81.
61. Hickey A.J., Misra A., Fourie P.B. Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis. J. Pharm. Sci. 2013, 102:3900-3907.
62. Olivier K.N., Shaw P.A., Glaser T.S., Bhattacharyya D., Fleshner M., Brewer C.C., Zalewski C.K., Folio L.R., Siegelman J.R., Shallom S., Park I.K., Sampaio E.P., Zelazny A.M., Holland S.M., Prevots D.R. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann. Am. Thorac. Soc. 2014, 11:30-35.
63. Arikace for nontuberculous mycobacteria (accessed 4/15/2014). http://www.clinicaltrials.gov/ct2/show/NCT01315236?term=Arikace&rank=4.
64. Conley J., Yang H., Wilson T., Blasetti K., DiNinno V., Schnell G., Wong J.P. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob. Agents Chemother. 1997, 41:1288-1292.
65. Talton J.D., Eppler B., Kirk J.F., Hammoud B.E., Matthews L., Dungan N., Waters C., Casper R.A., Richardson E., Suman J.D., De S., Reed M.D., Barr E., Kuehl P.J., Doyle-Eisele M., Roy C.J., Gardner D.L. Proc. Respir. Drug Deliv. 2010, 1:63-72.
66. Rijnders N.J., Cornelissen J.J., Slobbe L., Becker M.J., Doorduijn J.K., Hop W.C.J., Ruijgrok E.J., Luwenberg B., Vultos A., Lugtenburg P.J., de Marie S. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin. Infect. Dis. 2008, 46:1401-1408.
67. Kirkpatrick W.R., Najvar L.K., Vallor A.C., Wiederhold N.P., Bocanegra R., Pfeiffer J., Perkins K., Kugler A.R., Sweeney T.D., Patterson T.F. Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis. J. Antimicrob. Chemother. 2012, 67:970-976.
68. Tillotson G.S. Development of new antibacterials: a laudable aim, but what is the value?. Clin. Infect. Dis. 2010, 51:752.
69. Laxminarayan R., Duse A., Wattal C., Zaidi A.K.M., Wertheim H.F.L., Sumpradit N., Vlieghe E., Hara G.L., Gould I.M., Goossens H., Greko C., So A.D., Bigdeli M., Tomson G., Woodhouse W., Ombaka E., Peralta A.Q., Qamar F.N., Mir F., Kariuki S., Bhutta Z.A., Coates A., Bergstrom R., Wright G.D., Brown E.D., Cars O. Antibiotic resistance - the need for global solutions. Lancet Infect. Dis. 2013, 13:1057-1098.
70. VanDevanter D.R., Konstan M.W. Cystic fibrosis drug developers: victims of our own success. Proc. Respir. Drug Deliv. 2008, 2008(1):11-17.
71. Konstan M., Flume P.A., Kappler M., Chiron R., Higgins M., Brockhaus F., Zhang J., Angyalosi G., He E., Geller D.E. Safety, efficacy, and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J. Cyst. Fibros. 2011, 10:54-61.
72. Geller D.E., Nasr S.Z., Piggott S., Ho E., Angyalosi G., Higgins M. Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Respir. Care 2014, 59:388-398.
73. Schuster A., Haliburn C., Döring G., Goldman M.H. Safety, efficacy and convenience of colistimethate sdium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomized study. Thorax 2013, 68:344-350.
74. Dorkin H., Criollo M., Reimnitz P., Alder J., Hampel B. Randomised, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared with placebo in patients with cystic fibrosis - a Phase IIb study of ciprofloxacin dry powder for inhalation. Pediatr. Pulmonol. 2011, 46(Suppl. 34):235.
75. Tiddens H.A., Brody A.S. Monitoring cystic fibrosis lung disease in clinical trials: is it time for a change?. Proc. Am. Thorac. Soc. 2007, 4:297-298.
76. Donaldson S.H., Corcoran T.E., Laube B.L., Bennett W.D. Mucociliary clearance as an outcome measure for cystic fibrosis clinical research. Proc. Am. Thorac. Soc. 2007, 4:399-405.
77. Horsley A.R., Gustafsson P.M., Macleod K., Saunders C.J., Greening A.P., Porteous D., Davies J., Cunningham S., Alton E., Innes J.A. Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis. Thorax 2008, 63:135-140.
78. Vos W., De Backer J., Poli G., De Voler A., Ghys L., Van Holsbeke C., Vinchurkar S., De Backer L., De Backer W. Novel functional imaging of changes in small airways of patients treated with extrafine beclomethasone /formoterol. Respiration 2013, 86:393-401.
79. Montgomery A.B., Yeager M., Abuan T., Kollef M. The win-ratio method, a novel hierarchical endpoint for pneumonia trials in patients on mechanical ventilation 2014, ISICEM, (http://isicem.esn.eu/posters_listing/return_file/204.png, accessed 4/15/2014).
80. Geller D.E. Aerosol antibiotics in cystic fibrosis: yesterday, today, and tomorrow. Proc. Respir. Drug Deliv. 2008, 1:37-45.
81. Diot P., Palmer L.B., Smaldone A., DeCelie-Germana J., Grimson R., Smaldone G.C. RhDNase I aerosol deposition and related factors in cystic fibrosis. Am. J. Respir. Crit. Care Med. 1997, 156:1662-1668.
82. Newman S. Improving inhaler technique, adherence to therapy and the precision of dosing: major challenges for pulmonary drug delivery. Expert Opin. Drug Deliv. 2014, 11:365-378.
83. Lavorini F., Magnan A., Dubus J.C., Voshaar T., Corbetta L., Broeders M., Dekhuijzen R., Sanchis J., Viejo J.L., Barnes P., Corrigan C., Levy M., Crompton G.K. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir. Med. 2008, 102:593-604.
84. Molimard M., Raherison C., Lignot S., Depont F., Abouelfath A., Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J. Aerosol Med. 2003, 16:249-254.
85. Dixon J., Simpson I. Appealing to users - designing inhalers to maximize compliance and minimize misuse. Proc. Respir. Drug Deliv. Eur. 2009, 1:117-127.
86. Everard M.L. Aerosol therapy: regimen and device compliance in daily practice. Paediatr. Respir. Rev. 2006, 7S:S80-S82.
87. Geller D.E., Weers J.G., Heuerding S. Development of an inhaled dry powder formulation of tobramycin using PulmoSphere™ technology. J. Aerosol Pulm. Drug Deliv. 2011, 4:175-182.
88. Sawicki G.S., Sellers D.E., Robinson W.M. High treatment burden in adults with cystic fibrosis: challenges to disease management. J. Cyst. Fibros. 2009, 8:91-96.
89. Briesacher B.A., Quittner A.L., Saiman L., Sacco P., Fouayzi H., Quitell L.M. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm. Med. 2011, 11:5.
90. Ball R., Southern K.W., McCormick P., Duff A.J., Brownlee K.G., McNamara P.S. Adherence to nebulized therapies in adolescents with cystic fibrosis is best on week-days during school term time. J. Cyst. Fibros. 2013, 12:440-444.
91. Geller D.E. The science of aerosol delivery in cystic fibrosis. Pediatr. Pulmonol. 2008, 43:S5-S17.
92. Saiman L., Garber E. Infection control in cystic fibrosis: barriers to implementation. Curr. Opin. Pulm. Med. 2009, 1:626-631.
93. Lester M.K., Flume P.A., Gray S.L., Anderson D., Bowman C.M. Nebulizer use and maintenance by cystic fibrosis patients: a survey study. Respir. Care 2004, 49:1504-1508.
94. Blau H., Mussaffi H., Zahav M.M., Prais D., Livre M., Czitron B.M., Cohen H.A. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev. 2007, 491-495.
95. Kesser K.C., Geller D.E. New aerosol delivery devices for cystic fibrosis. Respir. Care 2009, 54:754-767.
96. Dhand R.L. Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J. Aerosol Med. Pulm. Drug Deliv. 2008, 21:45-60.
97. Lass J.S., Sant A., Knoch M. New advances in aerosolized drug delivery: vibrating membrane nebulizer technology. Expert Opin. Drug Deliv. 2006, 3:693-702.
98. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir. Care 2002, 47:1406-1416.
99. Keller M., Bucholski A., Seemann S., Schmitt A., Knoch M. Reduction in nebulisation time of aqueous drug solutions by the eFlow® rapid in comparison to a jet nebulizer to improve patient convenience and compliance. Eur. Respir. J. 2005, 26:338s.
100. McCoy K.S., Quittner A.L., Oermann C.M., Gibson R.L., Retsch-Bogart G.Z., Montgomery A.B. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2008, 178:921-928.
101. Rottier B.L., van Erp C.J.P., Sluyter T.S., Heijerman H.G., Frijlink H.W., deBoer A.H. Changes in performance of the PARI eFlow® rapid and PARI LC Plus during 6months use by CF patients. J. Aerosol Med. Pulm. Drug Deliv. 2009, 22:263-269.
102. Perkins W., Coates A.L. Performance of PARI e-Flow (Letters to the Editor). J. Aerosol Med. Pulm. Drug Deliv. 2010, 23:113-118.
103. Denyer J., Nikander K., Smith N.J. Adaptive aerosol delivery (AAD) technology. Expert Opin. Drug Deliv. 2004, 1:165-176.
104. 99mTc-DTPA. Proc. Drug Deliv. Lungs 2006, 17:206-209. (Edinburgh, Scotland).
105. McNamara P.S., McCormack P., McDonald A.J., Heaf L., Southern K.W. Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis. J. Cyst. Fibros. 2009, 8:258-263.
106. Bennett W.D. Controlled inhalation of aerosolized therapeutics. Expert Opin. Drug Deliv. 2005, 2:763-767.
107. Scheuch G., Muellinger B., Brand P., Sommerer K., Haeussermann S., Roeder S., Siekmeier R., Griese M., Meyer T. Inhaled drug delivery in cystic fibrosis is improved by controlled breathing pattern. Proc. Respir. Drug Deliv. Eur. IX 2005, 2:509-511.
108. Maltz D.S., Paboojian S.J. Device engineering insights into TOBI® Podhaler™: a development case study of high efficiency powder delivery to cystic fibrosis patients. Proc. Respir. Drug Deliv. Eur. 2011, 2011(1):55-66.
109. Haynes A., Ament B., Heng C., Le J., Ung K., Rao R., Malcolmson R., Weers J., Pavkov R., Heuerding S., Geller D.E. In vitro aerosol delivery performance of tobramycin inhalation powder for inhalation (TOBI® Podhaler™) using inspiratory flow profiles from cystic fibrosis patients. Pediatr. Pulmonol. 2013, 48(Suppl. 36):352.
110. Gupta A., Tarara T., Miller D., Reetz F., Gysler J., Weers J. A novel high payload dry powder formulation of ciprofloxacin for management of chronic lung infections. AAPS J. 2011, 13(Suppl. 2):R6156.
111. Stass H., Nagelschmitz J., Willman S., Delesen H., Gupta A., Baumann S. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. Clin. Drug Investig. 2013, 33:419-427.
112. Hoppentocht M., Hagedoorn P., Frijlink H.W., de Boer A.H. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur. J. Pharm. Biopharm. 2014, 86:23-30.
113. Broeders M., Molema J., Hop W., Folgering H. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. J. Aerosol Med. 2003, 16:131-141.
114. Everard M.L., Devadason S.G., Le Souef P.N. Flow early in the inspiratory maneuvre affects the aerosol particle size distribution from a Turbuhaler. Respir. Med. 1997, 91:624-628.
115. Standaert T.A., Speirs R.J., Rao N., Ung K., Tep V., Lin T., Rourke A.M. Young cystic fibrosis patients can effectively use a novel high-payload capsule-based dry powder inhaler with tobramycin powder for inhalation (TPI). Pediatr. Pulmonol. 2004, 27:284.
116. Duddu S.P., Sisk S.A., Walter Y.H., Tarara T.E., Trimble K., Clark A.R., Eldon M., Elton R.C., Pickford M., Hirst P.H., Newman S.P., Weers J.G. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere® powder. Pharm. Res. 2002, 19:689-695.
117. Weers J.G., Bell J., Chan H.K., Cipolla D., Dunbar C., Hickey A.J., Smith I.J. Pulmonary formulations: what remains to be done?. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23(Suppl. 2):S5-S23.
118. Weers J.G., Tarara T.E. The PulmoSphere platform for pulmonary drug delivery. Ther. Deliv. 2014, 5:277-295.
119. Weers J.G., Ung K., Le J., Rao N., Ament B., Axford G., Maltz D., Chan L. Dose emission characteristics of placebo PulmoSphere particles are unaffected by a subject's inhalation maneuver. J. Aerosol Med. Pulm. Drug Deliv. 2013, 26:56-68.
120. Young P.M., Crapper J., Philips G., Sharma K., Chan H.K., Traini D. Overcoming dose limitations using the Orbital multi-breath dry powder inhaler. J. Aerosol Med. Pulm. Drug Deliv. 2014, 27:138-147.
121. Friebel C., Steckel H. Single-use disposable dry powder inhalers for pulmonary drug delivery. Expert Opin. Drug Deliv. 2010, 7:1359-1372.
122. de Boer A.H., Hagedoorn P., Westerman E.M., Le Brun P.P.H., Heijerman H.G.M., Frijlink H.W. Testing and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for higher powder doses. Eur. J. Pharm. Sci. 2006, 28:171-178.
123. Westerman E.M., de Boer A.H., Le Brun P.P.H., Touw D.J., Roldaan A.C., Frijlink H.W., Heijerman H.G.M. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J. Cyst. Fibros. 2007, 6:284-292.
124. Trapnell B.C., McColley S.A., Kissner D.G., Rolfe M.W., Rosen J.M., McKivitt M., Moorehead L., Montgomery A.B., Geller D.E. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. Am. J. Respir. Crit. Care Med. 2012, 185:171-178.
125. Clancy J.P., Dupont L., Konstan M.W., Billings J., Fustik S., Gross C.H., Lymp J., Minic P., Quittner A.L., Rubenstein R.C., Young K.R., Saiman L., Burns J.L., Govan J.R., Ramsey B., Gupta R. Phase II studies of nebulized Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013, 68:818-825.
126. Galeva I., Konstan M.W., Higgins M., Angyalosi G., Brockhaus F., Piggott S., Thomas K., Chuchalin A.G. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Curr. Med. Res. Opin. 2013, 29:947-956.
127. Geller D.E., Flume P.A., Staab D., Fischer R., Loutit J.S., Conrad D.J. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 2011, 183:1510-1516.
128. Konstan M.W., Geller D.E., Minic P., Brockhaus F., Zhang J., Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatr. Pulmonol. 2011, 46:230-238.
129. Godden D.J., Borland C., Lowry R., Higenbottam T.W. Chemical specificity of coughing in man. Clin. Sci. 1986, 70:301-306.
130. Lowry R.H., Wood A.M., Higenbottam T.W. Effects of pH and osmolarity on aerosol-induced cough in normal volunteers. Clin. Sci. 1988, 74:373-376.
131. Eschenbacher W.L., Boushey H.A., Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am. Rev. Respir. Dis. 1984, 129:211-215.
132. TOBI technical monograph 1998, Pathogenesis Corporation.
133. A.B. Montgomery, Aminoglycoside and fosfomycin combination for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis, U.S. Patent 8,636,983, 2014.
134. Jaques A., Daviskas E., Turton J.A., McKay K., Cooper P., Stirling R.G., Robertson C.F., Bye P.T.P., LeSouef P.N., Shadbolt B., Anderson S.D., Charlton B. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008, 133:1388-1396.
135. Janssen K.J., Higashi K., Jansen J., Doering G., Elborn S., Calado F., Sagkriotis A., Angyalosi G., Balp M.M. Efficacy of inhaled antibiotics in CF patients with chronic P. aeruginosa infection: a network meta-analysis. Value Health 2013, 16:A619.
136. Harrison M.J., McCarthy M., Fleming C., Hickey C., Shortt C., Eustace J.A., Murphy D.M., Plant B.J. Improved tolerability, adherence, and reduced intravenous (IV) antibiotic usage in CF patients receiving inhaled versus nebulized antibiotic prophylaxis. A real world comparison of tobramycin inhaled powder (TIP) and tobramycin inhaled solution (TIS). J. Cyst. Fibros. 2013, 12(Suppl. 1):S67.
137. Tillotson G.S. Antibiotic resistance: the challenge from an industry perspective. Expert. Rev. Clin. Pharmacol. 2009, 2:119-123.
138. Ehrlich P. Chemo-therapeutics: scientific principles, methods, and results. Lancet 1913, 445-451.
139. Dong Y., Zhao X., Domagala J., Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacteriu, bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 1999, 43:1756-1758.
140. Blondeau J.M., Hansen G., Metzler K.L., Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J. Chemother. 2004, 16(Suppl. 3):1-19.
141. Hesje C.K., Tillotson G.S., Blondeau J.M. MICs, MPCs and PK/PDs: a match (sometimes) made in hosts. Expert Rev. Respir. Med. 2007, 1:7-16.
142. Firsch A.W., Tripp J.T., Barrett C.D., Pidgeon B.E. Specific polysaccharide content of pneumoni lungs. J. Exp. Med. 1942, 76:505-510.
143. Hansen G., Metzler K.L., Drlica K., Blondeau J.M. Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2003, 47:440-441.
144. Smith H.J., Nichol K.A., Hoban D.J., Zhanel G.G. Stretching the mutant prevention concentration (MPC) beyond its limits. J. Antimicrob. Chemother. 2003, 51:1323-1325.
145. Sader H., Jones N. Internal report from JMI Laboratories 2004.
146. Santre C., Georges H., Jacquier J.M., Leroy O., Beuscart C., Buguin D., Beaucaire G. Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily verus twice daily. Antimicrob. Agents Chemother. 1995, 39:264-267.
147. Dennesen P.J.W., van der Ven A.J.A.M., Kessels A.G.H., Ramsay G., Bonten M.J.M. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 2001, 163:1371-1375.
148. Ibrahim E.H., Ward S., Sherman G., Schaiff R., Fraser V., Kollef M.H. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit. Care Med. 2001, 29:1109-1115.
149. Kollef M.H. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit?. Clin. Infect. Dis. 2006, 43(Suppl. 2):S82-S88.
150. Kollef M.H., Hamilton C.W., Montgomery A.B. Aerosolized antibiotics: do they add to the treatment of pneumonia?. Curr. Opin. Infect. Dis. 2013, 26:538-544.
151. Rahal J.J. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin. Infect. Dis. 2006, 43(Suppl. 2):S95-S99.
152. Kanj S.S., Kanafani Z.A. Current concepts in antimicrobial therapy against resistant Gram-negative organisms: Extended spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug resistant Pseudomonas aeruginosa. Mayo Clin. Proc. 2011, 86:250-259.
153. Montgomery A.B., Rhomberg P., Abuan T., Jones R. Synergistic effects for a combination of amikacin and fosfomycin against selected Gram-negative pathogens. Am. J. Respir. Crit. Care Med. 2013, 187:A3236.
154. Mendelman P.M., Smith A.L., Levy J., Weber A., Ramsey B., Davis R.L. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Intensive Care Med. 2012, 38:263-271.
155. Bundtzen R.W., Gerber A.U., Cohn D.L., Craig W.A. Postantibiotic suppression of bacterial growth. Rev. Infect. Dis. 1981, 3:28-37.
156. Zhanel G.G., Hoban D.J., Harding G.K.M. The postantibiotic effect: a review of in vitro and in vivo data. Ann. Pharmacother. 1991, 25:153-163.
157. Smith A.L., Ramsey B.W., Hedges D.L., Hack B., Williams-Warren J., Weber A., Gore E.J., Redding G.J. Safety of aerosol tobramycin for 3months to patients with cystic fibrosis. Pediatr. Pulmonol. 1989, 7:265-271.
158. Ramsey B.W., Dorkin H.L., Eisenberg J.D., Gibson R.L., Harwood I.R., Kravitz R.M., Schidlow D.V., Wilmott R.W., Astley S.J., McBurnie M.A., Wentz K., Smith A.L. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J. Med. 1993, 328:1740-1746.
159. Smith A.L. Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation?. J. Cyst. Fibros. 2002, 1:S189-S193.
160. Elborn J.S., Henig N.R. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. Expert. Opin. Pharmacother. 2010, 11:1373-1385.
161. Niederman M.S. Is "crop rotation" of antibiotics the solution to a "resistant" problem in the ICU?. Am. J. Respir. Crit. Care Med. 1997, 156:1029-1031.
162. Phase 3 study of aztreonam for inhalation solution (AZLI) and continuous alternating therapy regimen for the treatment of chronic Pseudomonas aeruginosa infection in patients with CF (AZLI CAT) (accessed 4/15/2014). http://www.clinicaltrials.gov/ct2/show/NCT01641822?term=AZLI&rank=2.
163. Lacy M.K., Nicolau D.P., Nightengale C.H., Quintiliani R. The pharmacodynamics of aminoglycosides. Clin. Infect. Dis. 1998, 27:23-27.
164. Verpooten G.A., Giuliano R.A., Verbist L., Eestermans G., DeBroe M.E. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin. Pharmacol. Ther. 1989, 45:22-27.
165. Tobramycin inhalation powder (TIP) administered once daily continuously versus TIP administered BID in 28day on/28day off cycles accessed 4/15/2014. http://www.clinicaltrials.gov/ct2/show/NCT02015663?term=tobramycin+inhalation+powder&rank=2.
166. Lewis K. Riddle of biofilm resistance. Antimicrob. Agents Chemother. 2001, 45:999-1007.
167. Hurley M.N., Cámara M., Smyth A.R. Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur. Respir. J. 2012, 40:1014-1023.
168. Diggle S., Stacey R., Dodd C., Camara M., Williams P., Winzer K. The galactophilic lectin, LecA contributes to biofilm development in Pseudomonas aeruginosa. Environ. Microbiol. 2006, 8:1095-1104.
169. Kadam R.U., Bergmann M., Hurley M., Garg D., Cacciarini M., Swiderska M.A., Nativi C., Sattler M., Smyth A.R., Williams P., Camara M., Stocker A., Darbre T., Reymond J.L. A glycopeptide dendrimer inhibitor of the galactose-specific lectin LecA and of Pseudompnas aeruginosa biofilms. Angew. Chem. Int. Ed. Engl. 2011, 50:10631-10635.
170. Johansson E., Crusz S., Kolomiets E., Buts L., Kadam R.U., Cacciarini M., Bartels K.M., Diggle S.P., Camara M., Williams P., Loris R., Nativi C., Rosenau F., Jaeger K.E., Darbre T., Reymond J.L. Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LecB. Chem. Biol. 2008, 15:1249-1257.
171. Moreau-Marquid S., O'Toole G.A., Stanton B.A. Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am. J. Respir. Cell Mol. Biol. 2009, 41:305-313.
172. Kaneko Y., Thoendel M., Olakanmi O., Britigan B.E., Singh P.K. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J. Clin. Invest. 2007, 117:877-888.
173. Halwani M., Yebio B., Suntres Z.E., Alipour M., Azghani A.O., Omri A. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2008, 62:1291-1297.
174. Donlan R.M. Preventing biofilms of clinically relevant organisms using bacteriophages. Trends Microbiol. 2009, 17:66-72.
175. Hoe S., Semler D.D., Goudie A.D., Lynch K.H., Matinkoo S., Finlay W.H., Dennis J.J., Vehring R. Respirable bacteriophages for the treatment of bacterial lung infections. J. Aerosol Med. Pulm. Drug Deliv. 2013, 26:317-335.
176. Matinkoo S., Lynch K.H., Dennis J.J., Finlay W.H., Vehring R. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J. Pharm. Sci. 2011, 100:5197-5205.
177. N.S. Faithfull, J.G. Weers, Partial liquid breathing of fluorocarbons, U.S. Patent 5,490,498 (1996).
178. B. Fuhrman, Perfluorocarbon associated gas exchange, U.S. Patent 5,437,272 (1995).
179. Hirschl R.B., Conrad S., Kaiser R., Zwischenberger J.B., Bartlett R.H., Booth F., Cardenas V. Partial liquid ventilation in adult patients with ARDS: a multicenter Phase I-II trial. Ann. Surg. 1996, 228:692-700.
180. Gauger P.G., Pranikoff T., Schreiner R.J., Moler F.W., Hirschl R.B. Initial experience with partial liquid ventilation in pediatric patients with acute respiratory distress syndrome. Crit. Care Med. 1996, 24:16-22.
181. Weers J.G. A physicochemical evaluation of perfluorochemicals for oxygen transport applications. J. Fluor. Chem. 1993, 64:73-93.
182. Lehmler H.J. Anti-inflammatory effects of perfluorocarbon compounds. Expert Rev. Respir. Med. 2008, 2:273-289.
183. Cullen A.B., Cox C.A., Hipp S.J., Wolfson M.R., Shaffer T.H. Intratracheal delivery strategy of gentamicin with partial liquid ventilation. Respir. Med. 1999, 93:770-778.
184. Cox C.A., Cullen A.B., Wolfson M.R., Shaffer T.H. Intratracheal administration of perfluorochemical-gentamicin suspension: a comparison to intravenous administration in normal and injured lungs. Pediatr. Pulmonol. 2001, 32:142-151.
185. Smith D.J., Gambone L.M., Tarara T., Meays D.R., Dellamary L.A., Woods C.M., Weers J. Liquid dose pulmonary instillation of gentamicin PulmoSpheres formulations: tissue distribution and pharmacokinetics in rabbits. Pharm. Res. 2001, 18:1556-1561.
186. Dickson E.W., Heard S.O., Tarara T.E., Weers J.G., Brueggemann B.A., Doern G.V. Liquid ventilation with perflubron in the treatment of rats with pneumococcal pneumonia. Crit. Care Med. 2002, 30:393-395.
187. Dickson E.W., Doern G.V., Trevino L., Mazzoni M., Heard S.O. Prevention of descending pneumonia in rats with perflubron-delivered tobramycin. Acad. Emerg. Med. 2003, 10:1019-1023.
188. Jung R., Pendland S.L., Martin S.J. Combined bactericidal activity of perfluorooctyl bromide and aminoglycosides against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2002, 50:939-944.
189. Weers J.G., Tarara T.E., Gill H., English B.S., Dellamary L.A. Homodispersion technology for HFA suspensions: particle engineering to reduce dosing variance. Proc. Respir. Drug Deliv. Eur. VII 2000, 1:91-97.
190. Mazurek H., Chiron R., Kucerova T., Geidel C., Bolbas K., Chuchalin A., Blanco-Aparicio M., Santoro D., Varoli G., Zibellini M., Cicirello H., Antipkin Y.G. Long-term efficacy and safety of aerosolized tobramycin 300mg/4ml in cystic fibrosis. Pediatr. Pulmonol. 2014, (in press). 10.1002/ppul.22989.
191. Oermann C.M., Retsch-Bogart G.Z., Quittner A.L., Gibson R.L., McCoy K.S., Montgomery A.B., Cooper P.J. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr. Pulmonol. 2010, 45:1121-1134.
192. Kadrichu N., Boc S., Corkery K., Challoner P. In vitro efficiency of the Amikacin Inhale system, a novel integrated drug-device delivery system. Crit. Care 2013, 17:P81.
193. Chuchalin A., Csiszer E., Gyurkovics K., Bartnicka M.T., Sands D., Kopranov N., Varoli G., Preti P.A.M., Mazurek H. A formulation of aerosolized tobramycin (Bramitob®) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr. Drugs 2009, 9(Suppl. 1):21-31.
194. Li Z., Zhang Y., Wurtz W., Lee J.K., Malinin V.S., Durwas-Krishnan S., Meers P., Perkins W.R. Characterization of nebulized liposomal amikacin (Arikace™) as a function of droplet size. J. Aerosol Med. Pulm. Drug Deliv. 2008, 21:245-253.
195. Elborn J.S., Henig N.R. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. Expert. Opin. Pharmacother. 2010, 11:1373-1385.
196. Pulmaquin specifications (Exhibit D) (accessed 4/15/2014). http://investor.aradigm.com/secfiling.cfm?filingID=1193125-13-413586.
197. Geller D.E., Flume P.A., Griffith D.C., Morgan E., White D., Loutit J.S., Dudley M.N. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob. Agents Chemother. 2011, 55:2636-2640.
198. Ross D.L., Riley C.M. Physicochemical properties of the fluoroquinolone antimicrobials III. Complexation of lomefloxacin with various metal ions and the effect of metal ion complexation on aqueous solubility. Int. J. Pharm. 1992, 87:203-213.
199. accessed 4/15/2014. http://clinicaltrials.gov/show/NCT01746095.
200. Lenney W., Edenborough F., Kho P., Kovarik J.M. Lung deposition of inhaled tobramycin with eFlow Rapid/LC Plus jet nebulizer in healthy and cystic fibrosis subjects. J. Cyst. Fibros. 2011, 10:9-14.
201. Sethi S., Jones P.W., Theron M.S., Miravitlles M., Rubenstein E., Wedzicha J.A., Wilson R. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir. Res. 2010, 11:10.
202. Santré C., Georges H., Jacquier J.M., Leroy O., Beuscart C., Buguin D., Beaucaire G. Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily. Antimicrob. Agents Chemother. 1995, 39:264-267.
203. Rosenfeld M., Ramsey B.W., Gibson R.L. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr. Opin. Pulm. Med. 2003, 9:492-497.
204. Boushey H.A., Huang Y.J. The microbiome and airway disease: role in pathogenesis, presentation, and response to treatment. Proc. Respir. Drug Deliv. 2014, 2014(1):1-14.
205. Han M.K., Huang Y.J., Lipuma J.J., Boushey H.A., Boucher R.C., Cookson W.O., Curtis J.L., Erb-Downward J., Lynch S.V., Sethi S. Significance of the microbiome in obstructive lung disease. Thorax 2012, 67:456-463.
206. Huang Y.J., Lynch S.V. The emrging relationship between the airway microbiota and chronic respiratory disease: clinical implications. Expert Rev. Respir. Med. 2011, 5:809-821.
207. Duan K., Dammel C., Stein J., Rabin H., Surette M.G. Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol. Microbiol. 2003, 50:1477-1491.
208. Huang Y.J., Kim E., Cox M.J., Brodie E.L., Brown R., Wiener-Kronish J.P., Lynch S.V. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS 2010, 14:9-59.
209. Bilton D., Pressler T., Fajac I., Clancy J.P., Sands D., Minic P., Cipolli M., La Rosa M., Galeva I., Sole A., Dupont L., Goss C.H., Mayer-Hamblett N., Quittner A.L., Constantine S., Gupta R., Konstan M. Once daily liposomal amikacin for inhalation is noninferior to twice-daily tobramycin inhalation solution in improving pulmonary function in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa. J. Cyst. Fibros. 2014, 13(Suppl. 2):S15.
210. Montgomery A.B., Abuan T., Yeager M.A. Regulatory aspects of Phase 3 endpoints for new inhaled antibiotics for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections. J. Aerosol Med. Pulm. Drug Deliv. 2012, 25:198-203.